1-11 of 11
Dick de Zeeuw
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Systems Biology–Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes

Gert Mayer, Hiddo J.L. Heerspink, Constantin Aschauer, Andreas Heinzel, Georg Heinze, Alexander Kainz, Judith Sunzenauer, Paul Perco, Dick de Zeeuw, Peter Rossing, Michelle Pena, Rainer Oberbauer
Journal: Diabetes Care
Diabetes Care 2017;40(3):391–397
https://doi.org/10.2337/dc16-2202
Published: 11 January 2017
View article titled, Systems Biology–Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes
Open the PDF for Systems Biology–Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes

Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Kirk Ways, Mehul Desai, Wayne Shaw, George Capuano, Maria Alba, Joel Jiang, Frank Vercruysse, Gary Meininger, David Matthews, on behalf of the CANVAS Trial Collaborative Group
Journal: Diabetes Care
Diabetes Care 2015;38(3):403–411
https://doi.org/10.2337/dc14-1237
Published: 02 December 2014
View article titled, Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes
Open the PDF for Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Creatinine Excretion Rate and Mortality in Type 2 Diabetes and Nephropathy

Steef J. Sinkeler, MD, Arjan J. Kwakernaak, MD, Stephan J.L. Bakker, MD, Shahnaz Shahinfar, MD, Enric Esmatjes, MD, Dick de Zeeuw, MD, Gerjan Navis, MD, Hiddo J. Lambers Heerspink, PHARMD
Journal: Diabetes Care
Diabetes Care 2013;36(6):1489–1494
https://doi.org/10.2337/dc12-1545
Published: 15 May 2013
View article titled, Creatinine Excretion Rate and Mortality in Type 2 Diabetes and Nephropathy
Open the PDF for Creatinine Excretion Rate and Mortality in Type 2 Diabetes and Nephropathy in another window
Includes: Supplementary data
Journal Articles

Growth-Differentiation Factor 15 Predicts Worsening of Albuminuria in Patients With Type 2 Diabetes

Merel E. Hellemons, MD, Magdalena Mazagova, PHD, Ron T. Gansevoort, MD, Robert H. Henning, MD, Dick de Zeeuw, MD, Stephan J.L. Bakker, MD, Hiddo J. Lambers-Heerspink, PHD, Leo E. Deelman, PHD
Journal: Diabetes Care
Diabetes Care 2012;35(11):2340–2346
https://doi.org/10.2337/dc12-0180
Published: 13 October 2012
View article titled, Growth-Differentiation Factor 15 Predicts Worsening of Albuminuria in Patients With Type 2 Diabetes
Open the PDF for Growth-Differentiation Factor 15 Predicts Worsening of Albuminuria in Patients With Type 2 Diabetes in another window
Journal Articles

Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria: A post hoc analysis of the IRMA-2 trial

Merel E. Hellemons, MD, Frederik Persson, MD, Stephan J.L. Bakker, MD, Peter Rossing, MD, Hans-Henrik Parving, MD, Dick De Zeeuw, MD, Hiddo J. Lambers Heerspink, PHARMD
Journal: Diabetes Care
Diabetes Care 2011;34(9):2078–2083
https://doi.org/10.2337/dc11-0324
Published: 19 August 2011
View article titled, Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria: <subtitle>A post hoc analysis of the IRMA-2 trial</subtitle>
Open the PDF for Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria: <subtitle>A post hoc analysis of the IRMA-2 trial</subtitle> in another window
Journal Articles

Comment on: Ekinci et al. Dietary Salt Intake and Mortality in Patients With Type 2 Diabetes. Diabetes Care 2011;34:703–709

Hiddo J. Lambers Heerspink, PHARMD PHD, Arjan Kwakernaak, MD PHD, Dick de Zeeuw, MD PHD, Gerjan Navis, MD PHD
Journal: Diabetes Care
Diabetes Care 2011;34(7):e124–124
https://doi.org/10.2337/dc11-0711
Published: 17 June 2011
View article titled, Comment on: Ekinci et al. Dietary Salt Intake and Mortality in Patients With Type 2 Diabetes. Diabetes Care 2011;34:703–709
Open the PDF for Comment on: Ekinci et al. Dietary Salt Intake and Mortality in Patients With Type 2 Diabetes. Diabetes Care 2011;34:703–709 in another window
Journal Articles

Monitoring Kidney Function and Albuminuria in Patients With Diabetes

Hiddo J. Lambers Heerspink, PHARMD, Frank A. Holtkamp, PHARMD, Dick de Zeeuw, MD, Mordchai Ravid, MD
Journal: Diabetes Care
Diabetes Care 2011;34(Supplement_2):S325–S329
https://doi.org/10.2337/dc11-s247
Published: 22 April 2011
View article titled, Monitoring Kidney Function and Albuminuria in Patients With Diabetes
Open the PDF for Monitoring Kidney Function and Albuminuria in Patients With Diabetes in another window
Journal Articles

Albuminuria: A Great Risk Marker, but an Underestimated Target in Diabetes

Dick de Zeeuw, MD, Itamar Raz, MD
Journal: Diabetes Care
Diabetes Care 2008;31(Supplement_2):S190–S193
https://doi.org/10.2337/dc08-s248
Published: 01 February 2008
View article titled, Albuminuria: A Great Risk Marker, but an Underestimated Target in Diabetes
Open the PDF for Albuminuria: A Great Risk Marker, but an Underestimated Target in Diabetes in another window
Journal Articles

Change in Albuminuria Is Predictive of Cardiovascular Outcome in Normotensive Patients With Type 2 Diabetes and Microalbuminuria

Adrienne A.M. Zandbergen, MD, PHD, Liffert Vogt, MD, Dick de Zeeuw, MD, PHD, Steven W.J. Lamberts, MD, PHD, Rob J.T.H. Ouwendijk, MD, PHD, Marinus G.A. Baggen, MD, PHD, Aart H. Bootsma, MD, PHD
Journal: Diabetes Care
Diabetes Care 2007;30(12):3119–3121
https://doi.org/10.2337/dc07-0960
Published: 01 December 2007
View article titled, Change in Albuminuria Is Predictive of Cardiovascular Outcome in Normotensive Patients With Type 2 Diabetes and Microalbuminuria
Open the PDF for Change in Albuminuria Is Predictive of Cardiovascular Outcome in Normotensive Patients With Type 2 Diabetes and Microalbuminuria in another window
Journal Articles

Urinary Albumin Excretion and Its Relation With C-Reactive Protein and the Metabolic Syndrome in the Prediction of Type 2 Diabetes

Auke H. Brantsma, MD, Stephan J.L. Bakker, MD, PHD, Hans L. Hillege, MD, PHD, Dick de Zeeuw, MD, PHD, Paul E. de Jong, MD, PHD, Ronald T. Gansevoort, MD, PHD, the PREVEND Study Group
Journal: Diabetes Care
Diabetes Care 2005;28(10):2525–2530
https://doi.org/10.2337/diacare.28.10.2525
Published: 01 October 2005
View article titled, Urinary Albumin Excretion and Its Relation With C-Reactive Protein and the Metabolic Syndrome in the Prediction of Type 2 Diabetes
Open the PDF for Urinary Albumin Excretion and Its Relation With C-Reactive Protein and the Metabolic Syndrome in the Prediction of Type 2 Diabetes in another window
Journal Articles

Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive Medications Excluding ACE Inhibitors, Other Angiotensin-2 Receptor Antagonists, and Dihydropyridine Calcium Channel Blockers) or Late Irbesartan Treatment in Patients With Type 2 Diabetes, Hypertension, and Renal Disease

Andrew J. Palmer, BSC, MBBS, Lieven Annemans, PHD, Stéphane Roze, MS, Mark Lamotte, MD, Pablo Lapuerta, MD, Roland Chen, MD, Sylvie Gabriel, MD, Paulo Carita, PHD, Roger A. Rodby, MD, Dick de Zeeuw, MD, PHD, Hans-Henrik Parving, MD
Journal: Diabetes Care
Diabetes Care 2004;27(8):1897–1903
https://doi.org/10.2337/diacare.27.8.1897
Published: 01 August 2004
View article titled, Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive Medications Excluding ACE Inhibitors, Other Angiotensin-2 Receptor Antagonists, and Dihydropyridine Calcium Channel Blockers) or Late Irbesartan Treatment in Patients With Type 2 Diabetes, Hypertension, and Renal Disease
Open the PDF for Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive Medications Excluding ACE Inhibitors, Other Angiotensin-2 Receptor Antagonists, and Dihydropyridine Calcium Channel Blockers) or Late Irbesartan Treatment in Patients With Type 2 Diabetes, Hypertension, and Renal Disease in another window
Includes: Supplementary data